Yahoo · Sep 2, 2026
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
NASDAQ · TMO
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$608.54
Up+$8.04 (+1.34%)
Updated Sep 3, 2026, 5:50 AM
SID Score
7.1/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 219.39B
- P/E ratio
- 33.3
- Dividend yield
- 0.35%
- 52-week range
- $435.27 – $647.00
- Volume
- 1.62M
- Avg. volume
- 2.05M
Price performance
TMO price history
1M range · 21 trading sessions · Daily adjusted prices
TMO closed at $608.54 after 21 trading sessions, up 5.31% for the selected period.
- Last close
- $608.54
- Period change
- +5.31%
- Period low
- $577.83
- Period high
- $633.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $601.63 | $614.5975 | $600.70 | $608.54 | 1.62M |
| Sep 1, 2026 | $619.00 | $621.00 | $599.52 | $600.50 | 1.39M |
| Aug 31, 2026 | $614.38 | $620.715 | $610.35 | $617.10 | 1.43M |
| Aug 28, 2026 | $626.58 | $630.00 | $617.45 | $622.18 | 1.02M |
| Aug 27, 2026 | $629.47 | $637.13 | $626.33 | $630.70 | 1.47M |
| Aug 26, 2026 | $622.23 | $636.06 | $622.23 | $633.71 | 1.84M |
| Aug 25, 2026 | $631.01 | $647.00 | $618.0303 | $628.15 | 1.54M |
| Aug 24, 2026 | $630.00 | $630.00 | $615.97 | $628.74 | 1.73M |
| Aug 21, 2026 | $626.48 | $629.51 | $616.27 | $629.27 | 1.56M |
| Aug 20, 2026 | $609.85 | $634.70 | $607.37 | $627.55 | 2.75M |
| Aug 19, 2026 | $595.11 | $620.475 | $594.995 | $613.54 | 2.51M |
| Aug 18, 2026 | $588.87 | $592.22 | $584.86 | $589.04 | 1.72M |
| Aug 17, 2026 | $582.55 | $592.32 | $580.00 | $585.51 | 887.3K |
| Aug 14, 2026 | $592.11 | $594.74 | $587.51 | $588.29 | 1.06M |
| Aug 13, 2026 | $606.29 | $606.75 | $593.39 | $595.89 | 1.45M |
| Aug 12, 2026 | $599.21 | $604.19 | $595.00 | $603.01 | 1.53M |
| Aug 11, 2026 | $599.99 | $606.21 | $594.81 | $605.00 | 1.66M |
| Aug 10, 2026 | $588.53 | $599.69 | $588.53 | $599.69 | 1.86M |
| Aug 7, 2026 | $578.00 | $594.26 | $574.7679 | $594.00 | 2.21M |
| Aug 6, 2026 | $576.80 | $580.31 | $569.63 | $580.02 | 1.72M |
| Aug 5, 2026 | $567.93 | $578.00 | $564.402 | $577.83 | 1.55M |
Latest TMO news
The latest Smart Investors Daily articles mentioning TMO.
Stock researchCompany · Overview
TMO research
Overview
Company profile and research snapshot.
Company profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $625.78
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | RBC Capital | Sector Perform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Yahoo · Sep 2, 2026
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 2, 2026
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach
GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.
AI research layers
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares traded at $600.50, reflecting a single-session decline of approximately 1.05%, per SID market data. Despite the near-term pullback, the stock has demonstrated sustained momentum over multiple timeframes, gaining 7.45% over the past month and 24.91% over the trailing three months, according to Massive/Polygon data. On a twelve-month basis, TMO has posted a more modest return of 7.28%. The stock currently trades well above both its 50-day moving average of $560.53 and its 200-day moving average of $528.15, indicating a constructive intermediate-term trend. The 14-day relative strength index stands at 57.0, positioning the stock in neutral territory without signaling overbought or oversold conditions. Average daily trading volume registers at approximately 2.05 million shares. The company carries a market capitalization of roughly $219.4 billion and maintains a beta of 0.902, reflecting slightly below-market volatility relative to broader equity benchmarks.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific currently trades at a price-to-earnings ratio of 33.30, positioning it at a premium relative to the broader Healthcare sector, per SID market data. The price-to-book ratio stands at 4.29, according to SEC filings, reflecting investor willingness to pay a meaningful premium above net asset value for the company's diversified life sciences portfolio. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple is not well supported by near-term earnings growth expectations. On the income distribution front, TMO offers a modest dividend yield of approximately 0.29%, indicating the company prioritizes capital reinvestment and strategic acquisitions over shareholder distributions. At a market capitalization of $219.4 billion, Thermo Fisher remains one of the largest pure-play life sciences and analytical instruments companies globally. These valuation metrics collectively reflect a mature business trading at growth-oriented multiples within a capital-intensive industry.
Smart Money Activity for TMO
Thermo Fisher Scientific registers a composite smart money score of 55 out of 100, corresponding to a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong institutional ownership and conviction among large fund managers, according to 13F institutional filings. In contrast, the insider trading component scores just 9.7 out of 25, weighed down by a pronounced selling imbalance. SEC Form 4 filings reveal 20 insider transactions over the past 90 days, comprising only 2 purchases against 18 sales, reflecting a clear pattern of insider distribution. The dark pool activity score stands at 8.5 out of 25, suggesting relatively subdued off-exchange accumulation. Congressional trading activity scores 11.6 out of 25, indicating moderate but not exceptional interest from legislators disclosing equity positions. The divergence between robust institutional backing and persistent insider selling presents a mixed directional signal that warrants ongoing monitoring from market participants tracking smart money flows.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has delivered consecutive earnings beats in its most recently reported quarters, according to company earnings reports. In the most recent quarter reported on July 23, 2026, the company posted earnings per share of $6.03, exceeding analyst estimates of $5.71 by $0.32, representing a positive surprise of approximately 5.6%. The prior quarter, reported on April 23, 2026, showed EPS of $5.44 against a consensus estimate of $5.23, delivering a $0.21 upside surprise. Looking ahead, analyst estimates project EPS of $5.71 for the upcoming quarter with results expected on July 22, 2026, and $5.29 for the following period anticipated on April 22, 2026. The consistent pattern of above-consensus results suggests effective operational execution and disciplined cost management. These forward estimates, per analyst consensus data, will serve as critical benchmarks for evaluating whether Thermo Fisher can sustain its recent trajectory of outperformance against Wall Street expectations.
Wall Street Analyst Ratings for TMO
Wall Street analyst coverage of Thermo Fisher Scientific reflects a generally constructive outlook, with the majority of recent ratings maintaining favorable positioning, per SID consensus data. On July 27, 2026, Morgan Stanley reiterated its Overweight rating, while Barclays also maintained an Overweight designation on July 24, 2026, according to Wall Street analyst reports. Evercore ISI Group reaffirmed its Outperform rating on July 6, 2026, adding to the bullish contingent. On the more cautious side, Piper Sandler maintained a Neutral rating on July 27, 2026, and RBC Capital held its Sector Perform rating on July 24, 2026. Notably, none of the five most recent analyst actions involved rating changes, with all firms reiterating prior positions, suggesting a period of consensus stability. Of the five tracked ratings, three carry bullish-leaning designations while two reflect neutral stances, indicating that a meaningful majority of covering analysts maintain constructive views on the stock's risk-reward profile at current levels.
